Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spevatamig - Phanes Therapeutics

Next Previous
Drug Profile

Spevatamig - Phanes Therapeutics

Alternative Names: Anti-claudin18.2/anti-CD47 bispecific antibody; PT-886

Latest Information Update: 16 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phanes Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Adenocarcinoma
  • Phase I Cancer
  • Preclinical Pancreatic cancer

Most Recent Events

  • 16 Sep 2024 Phase-I/II clinical trials in Adenocarcinoma (First-line therapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable, Combination therapy) in USA (Parenteral) (NCT05482893)
  • 16 Sep 2024 Phase-I/II clinical trials in Adenocarcinoma (Late-stage disease, Metastatic disease, Combination therapy, Inoperable/Unresectable, Second-line therapy or greater) in USA (Parenteral) (NCT05482893)
  • 09 Sep 2024 Phase-I clinical trials in Cancer in China (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top